Matthew J. Farrell

Matthew J. Farrell

Auto-generated profile, based on publicly available information

Matthew J. Farrell

University of California, Los Angeles, Department of Radiation Oncology, Los Angeles, CA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Clinical Lung Cancer
Verified
Journal Article
Closed access
MFMatthew J. Farrell
Matthew J. Farrell
JYJehan B. Yahya
Jehan B. Yahya
CDCatherine Degnin
Catherine Degnin
YCYiyi Chen
Yiyi Chen
JHJohn M. Holland
John M. Holland
TMTimur Mitin
Timur Mitin

10 November 2023 in Journal of Clinical Oncology
Verified
Journal Article
Open access
SRSoumyajit Roy
Soumyajit Roy
TRTahmineh Romero
Tahmineh Romero
JMJeff Michalski
Jeff Michalski
FFFelix Y. Feng
Felix Y. Feng
JEJason A. Efstathiou
Jason A. Efstathiou
OIon behalf of the Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium Investigators
on behalf of the Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium Investigators
PURPOSE: The surrogacy of biochemical recurrence (BCR) for overall survival (OS) in localized prostate cancer remains controversial. Herein, we evaluate the surrogacy of BCR using different surrogacy analytic methods. MATERIALS AND METHODS: Individual patient data from 11 trials evaluating radiotherapy dose escalation, androgen deprivation therapy (ADT) use, and ADT prolongation were obtained. Surrogate candidacy was assessed using the Prentice criteria (including landmark analyses) and the two-stage meta-analytic approach (estimating Kendall's tau and the R2). Biochemical recurrence-free survival (BCRFS, time from random assignment to BCR or any death) and time to BCR (TTBCR, time from random assignment to BCR or cancer-specific deaths censoring for noncancer-related deaths) were assessed. RESULTS: Overall, 10,741 patients were included. Dose escalation, addition of short-term ADT, and prolongation of ADT duration significantly improved BCR (hazard ratio [HR], 0.71 [95% CI, 0.63 to 0.79]; HR, 0.53 [95% CI, 0.48 to 0.59]; and HR, 0.54 [95% CI, 0.48 to 0.61], respectively). Adding short-term ADT (HR, 0.91 [95% CI, 0.84 to 0.99]) and prolonging ADT (HR, 0.86 [95% CI, 0.78 to 0.94]) significantly improved OS, whereas dose escalation did not (HR, 0.98 [95% CI, 0.87 to 1.11]). BCR at 48 months was associated with inferior OS in all three groups (HR, 2.46 [95% CI, 2.08 to 2.92]; HR, 1.51 [95% CI, 1.35 to 1.70]; and HR, 2.31 [95% CI, 2.04 to 2.61], respectively). However, after adjusting for BCR at 48 months, there was no significant treatment effect on OS (HR, 1.10 [95% CI, 0.96 to 1.27]; HR, 0.96 [95% CI, 0.87 to 1.06] and 1.00 [95% CI, 0.90 to 1.12], respectively). The patient-level correlation (Kendall's tau) for BCRFS and OS ranged between 0.59 and 0.69, and that for TTBCR and OS ranged between 0.23 and 0.41. The R2 values for trial-level correlation of the treatment effect on BCRFS and TTBCR with that on OS were 0.563 and 0.160, respectively. CONCLUSION: BCRFS and TTBCR are prognostic but failed to satisfy all surrogacy criteria. Strength of correlation was greater when noncancer-related deaths were considered events.

1 September 2020 in Clinical Lung Cancer
Verified
Journal Article
Closed access
MFMatthew J. Farrell
Matthew J. Farrell
JYJehan B. Yahya
Jehan B. Yahya
CDCatherine Degnin
Catherine Degnin
YCYiyi Chen
Yiyi Chen
JHJohn M. Holland
John M. Holland
TMTimur Mitin
Timur Mitin

26 March 2025 in Health and Quality of Life Outcomes
Verified
Journal Article
Open access
PDF file
NKNicki Karimi-Mostowfi
Nicki Karimi-Mostowfi
FCFang-I Chu
Fang-I Chu
TWTrudy C. Wu
Trudy C. Wu
MFMatthew J. Farrell
Matthew J. Farrell
WAWisdom Akingbemi
Wisdom Akingbemi
ARAnn C. Raldow
Ann C. Raldow
Purpose: To examine racial and ethnic disparities in Health-Related Quality of Life (HRQOL) in older adults with breast cancer, both pre- and post-diagnosis. Methods: Using the SEER-MHOS database, we included patients ≥ 65 years old with breast cancer who completed the Health Outcomes Survey within 24 months pre- and post-diagnosis, and who were non-Hispanic White, non-Hispanic Asian or Pacific Islander, non-Hispanic Black or African American, or Hispanic. HRQOL data was measured via the Physical and Mental Component Summary (PCS, MCS). Univariable and multivariable linear regression models were fitted to assess for potential disparities between races and ethnicities. Results: On univariable regression models, a numerical drop in mean scores of PCS and MCS was found among all racial/ethnic groups between pre- and post-diagnosis. Among patients in the pre-diagnosis cohort who would be diagnosed with stage IV breast cancer, race was found to be a predictor of PCS with overall significance (p = 0.04). On the local test, compared with Black individuals, White individuals had higher pre-diagnosis PCS scores (+ 13.32, p = 0.03). Race/ethnicity was not found to be a predictor in PCS or MCS scores otherwise. Conclusion: Among older patients diagnosed with stage IV breast cancer, White individuals had better physical HRQOL than Black patients’ pre-diagnosis. The decrease in the numerical HRQOL scores of the physical domain in all groups post-diagnosis highlights the potential negative physical impact of breast cancer has on patients, demonstrating the need for determining the proper resources and support to improve physical HRQOL following diagnosis.

3 April 2025 in New England Journal of Medicine
Verified
Journal Article
Closed access
MFMatthew J. Farrell
Matthew J. Farrell
TWTrudy C. Wu
Trudy C. Wu
ARAnn C. Raldow
Ann C. Raldow

28 November 2023 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PDF file
TWTrudy C. Wu
Trudy C. Wu
MFMatthew J. Farrell
Matthew J. Farrell
NKNicki Karimi-Mostowfi
Nicki Karimi-Mostowfi
BCBasil H. Chaballout
Basil H. Chaballout
WAWisdom O. Akingbemi
Wisdom O. Akingbemi
ARAnn C. Raldow
Ann C. Raldow
Background: It is unclear whether health-related quality of life (HRQOL) disparities exist between racial/ethnic groups in older patients with esophageal cancer, pre- and post-diagnosis. Methods: Using the SEER-MHOS (Surveillance, Epidemiology, and End Results and Medicare Health Outcomes Survey) national database, we included patients ages 65-years-old or greater with esophageal cancer diagnosed from 1996 to 2017. HRQOL data within 36 months before and after diagnosis were measured by the Physical Component Summary (PCS) and Mental Component Summary (MCS) scores from the SF-36 and VR-12 instruments. Total combined score (TCS) was reflected by both PCS and MCS. Results: We identified 1,312 patients, with evaluable data on 873 patients pre-diagnosis and 439 post-diagnosis. On pre-diagnosis cohort MVA, the MCS was better for White over Hispanic patients (54.1 vs. 48.6, P = 0.012). On post-diagnosis cohort MVA, PCS was better for Hispanic compared with White (39.8 vs. 34.5, P = 0.036) patients, MCS was better for Asian compared with White (48.9 vs. 40.9, P = 0.034) patients, and TCS better for Asian compared with White (92.6 vs. 76.7, P = 0.003) patients. Conclusions: In older patients with esophageal cancer, White patients had better mental HRQOL as compared with Hispanic patients pre-diagnosis. However, post-diagnosis, White patients had worse mental and physical HRQOL compared with Asian and Hispanic patients, respectively, suggesting a greater negative impact on self-reported HRQOL in White patients with esophageal cancer. Impact: To our knowledge, this study is the first to explore HRQOL differences in patients with esophageal cancer of various racial and ethnic groups and warrants further validation in future studies.